Decreased and Variable Systemic Availability of Zidovudine in Patients with AIDS if Administered with a Meal

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1991 Jan 1

PMID 2060570

Citations 13

Authors

E Lotterer

M Ruhnke

M Trautmann

R Beyer

F E Bauer

Affiliations

Soon will be listed here.

Abstract

The systemic availability of oral zidovudine has been studied in 13 patients with the acquired immunodeficiency syndrome (AIDS) dosed either fasting or with breakfast. The mean peak plasma concentration and AUC of zidovudine were significantly 2.8- and 1.4-times higher in fasting patients than in those treated during meal. In both conditions the mean half-life was about 1.5 h and the period of plasma zidovudine concentrations greater than 1 mumol.l-1 was 2 h (NS). It is concluded that if zidovudine is taken on an empty stomach, high peak plasma concentrations and decreased variation in pharmacological parameters may be expected. Whether or not this will influence toxicity and efficacy remains to be shown.

Citing Articles

Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses.

Wiesner A, Skronska M, Gawlik G, Marcinkowska M, Zagrodzki P, Pasko P AIDS Behav. 2022; 27(5):1441-1468.

PMID: 36318429 PMC: 10129904. DOI: 10.1007/s10461-022-03880-6.

Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.

Moreno S, Hernandez B, Dronda F Drugs. 2007; 67(10):1441-62.

PMID: 17600392 DOI: 10.2165/00003495-200767100-00006.

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.

Kakuda T, Page L, Anderson P, Henry K, Schacker T, Rhame F Antimicrob Agents Chemother. 2000; 45(1):236-42.

PMID: 11120972 PMC: 90267. DOI: 10.1128/AAC.45.1.236-242.2001.

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Fleisher D, Li C, Zhou Y, Pao L, Karim A Clin Pharmacokinet. 1999; 36(3):233-54.

PMID: 10223170 DOI: 10.2165/00003088-199936030-00004.

Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.

Kaul S, Christofalo B, Raymond R, STEWART M, Macleod C Antimicrob Agents Chemother. 1998; 42(9):2295-8.

PMID: 9736552 PMC: 105822. DOI: 10.1128/AAC.42.9.2295.

References

Blum M, Liao S, Good S, de Miranda P . Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988; 85(2A):189-94. View

Anderson K . Influences of diet and nutrition on clinical pharmacokinetics. Clin Pharmacokinet. 1988; 14(6):325-46. DOI: 10.2165/00003088-198814060-00002. View

Collins J, Unadkat J . Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet. 1989; 17(1):1-9. DOI: 10.2165/00003088-198917010-00001. View

Langtry H . Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989; 37(4):408-50. DOI: 10.2165/00003495-198937040-00003. View

Klecker Jr R, Collins J, Yarchoan R, Thomas R, Jenkins J, Broder S . Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987; 41(4):407-12. DOI: 10.1038/clpt.1987.49. View

Welling P . Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm. 1977; 5(4):291-334. DOI: 10.1007/BF01061694. View

Yarchoan R, Mitsuya H, Myers C, Broder S . Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989; 321(11):726-38. DOI: 10.1056/NEJM198909143211106. View

Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D . Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986; 1(8481):575-80. DOI: 10.1016/s0140-6736(86)92808-4. View

Richman D, Fischl M, GRIECO M, Gottlieb M, Volberding P, Laskin O . The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):192-7. DOI: 10.1056/NEJM198707233170402. View

10.

Fischl M, Richman D, GRIECO M, Gottlieb M, Volberding P, Laskin O . The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):185-91. DOI: 10.1056/NEJM198707233170401. View

11.

Spire B, Dormont D, Barre-Sinoussi F, Montagnier L, Chermann J . Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Lancet. 1985; 1(8422):188-9. DOI: 10.1016/s0140-6736(85)92026-4. View

12.

McLean A, McNamara P, duSouich P, Gibaldi M, Lalka D . Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther. 1978; 24(1):5-10. DOI: 10.1002/cpt19782415. View

13.

Nakashima H, Matsui T, Harada S, Kobayashi N, Matsuda A, Ueda T . Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro. Antimicrob Agents Chemother. 1986; 30(6):933-7. PMC: 180622. DOI: 10.1128/AAC.30.6.933. View

14.

. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. MMWR Morb Mortal Wkly Rep. 1986; 35(20):334-9. View

15.

Mitsuya H, Weinhold K, Furman P, St Clair M, Lehrman S, Gallo R . 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985; 82(20):7096-100. PMC: 391317. DOI: 10.1073/pnas.82.20.7096. View